The FDA has approved Shire’s Lialda (mesalamine) indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Lialda is the first and only FDA-approved once-daily oral formulation of mesalamine. Shire will launch Lialda in the US during the first quarter of 2007.
Stiefel Laboratories received FDA approval for Olux-E (clobetasol propionate) foam, indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, also known as psoriasis and eczema, in patients 12 years of age or older. Steifel said Olux-E is will be available in U.S. pharmacies by March 2007 in 50 g and 100 g canisters.